Novel TNF antagonists for the treatment of rheumatoid arthritis

Statkute, Laisvyde; Ruderman, Eric

doi:10.1517/13543780903438559

Cited by 14 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two new TNF inhibitors, golimumab (a fully human anti-TNF␣ monoclonal antibody) and certolizumab pegol (a PEGylated FabЈ fragment of a humanized anti-TNF monoclonal antibody), have more recently been shown to be effective in the treatment of RA (83)(84)(85)(86)(87)(88). Thus, TNF␣ has clearly been proven to be a good target for RA treatment and has fulfilled the expectations raised during the preclinical studies performed in animal models.…”

Section: From Animal Models Toward the Clinicmentioning

confidence: 99%

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

Bevaart¹,

Vervoordeldonk²,

Tak³

2010

Arthritis & Rheumatism

231

193

View full text Add to dashboard Cite

There are accumulating data describing the association between diabetes and cancer mortality from Westernised populations. There are no data describing the relationship between diabetes and cancer mortality in African or South Asian populations from developing countries. We explored the relationship of abnormal glucose tolerance and diabetes on cancer mortality risk in a large, multi‐ethnic cohort from the developing nation of Mauritius. Population‐based surveys were undertaken in 1987, 1992 and 1998. The 9559 participants comprised 66% of South Asian (Indian), 27% of African (Creole), and 7% of Chinese descent. Cox's proportional hazards model with time varying covariates was used to obtain hazard ratios (HRs) and 95% confidence intervals (95% CI) for risk of cancer mortality, after adjustment for confounding factors. In men, but not women, cancer mortality risk increased with rising 2h‐PG levels with HR for the top versus bottom quintile of 2.77 (95%CI: 1.28 to 5.98). South Asian men with known diabetes had a significantly greater risk of cancer mortality than those with normal glucose tolerance (NGT) HR: 2.74 (95%CI: 1.00‐7.56). Overall, impaired glucose tolerance was associated with an elevated risk of cancer mortality compared to NGT (HR: 1.47, 95% CI: 0.98–2.19), though this was not significant. We have shown that the association between abnormal glucose tolerance and cancer extends to those of African and South Asian descent. These results highlight the importance of understanding this relationship in a global context to direct future health policy given the rapid increase in type 2 diabetes, especially in developing nations.

show abstract

Section: From Animal Models Toward the Clinicmentioning

confidence: 99%

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

Bevaart¹,

Vervoordeldonk²,

Tak³

2010

Arthritis & Rheumatism

231

193

View full text Add to dashboard Cite

show abstract

“…Clinical trials with this intravenous anti-TNFa therapy have been conducted in patients with uveitis, severe persistent asthma, rheumatoid arthritis, psoriasic arthritis and ankylosing spondylitis. Evaluation of the safety and efficacy of golimumab in sarcoidosis patients with chronic cutaneous and respiratory involvement resistant to conventional treatments is planned [66][67][68].…”

Section: Tnfa Inhibitorsmentioning

confidence: 99%

Cytokine modulators in the treatment of sarcoidosis

2011

View full text Add to dashboard Cite

Sarcoidosis is a granulomatous lung disease in which several cytokines play a pivotal pathogenetic role. Steroid-resistant disease can be treated with immunosuppressive drugs, antimalarial therapies and recently with anti-TNFα agents. The use of biological agents for the treatment of sarcoidosis springs from research into the pathogenesis of the disease and also from the experience of rheumatologists with other chronic inflammatory diseases. Rituximab, golimumab and ustekinumab are cytokine modulators, useful in the treatment of immunoinflammatory disorders, for which randomized trials to evaluate safety and efficacy in sarcoidosis are not yet available. Novel anticytokine drugs administered alone or in association may offer a new approach to treatment of the disease. This review focuses on recent advances in anti-TNFα agents and cytokine modulators for the treatment of sarcoidosis and their therapeutic prospects.

show abstract

“…Mild increases in LFTs were more consistently observed with infliximab, less commonly with adalimumab and were not observed with etanercept in comparison with DMARDS (category B, C evidence, (Furst DE, 2008 1621 /id; Sokolove J, 2008 466 /id; Sokolove, 2010 42 /id)). Golimumab toxicity is associated with LFT increases (category A, C, D evidence416–421). The use of concomitant drugs and other clinical conditions confound the interpretation of this observation (FDA; category B and C evidence352 422–427).…”

Section: Haematologicalmentioning

confidence: 99%